Inspection readiness refers to the state of preparedness a clinical research organization or sponsor maintains to undergo regulatory inspections at any time. It involves having all necessary documentation, processes, and systems in place and readily accessible for review by regulatory authorities such as the FDA or EMA.
This state of readiness requires ongoing maintenance of trial master files, standard operating procedures, and training records. It also encompasses the ability to demonstrate compliance with Good Clinical Practice (GCP) guidelines and applicable regulations throughout the entire clinical trial process.
Inspection readiness is crucial in clinical research as it ensures compliance with regulatory requirements and maintains data integrity. It helps organizations avoid costly delays, fines, or even trial suspension that could result from failed inspections, thus protecting both patient safety and the integrity of clinical study results.
Furthermore, maintaining a state of inspection readiness fosters a culture of quality and continuous improvement within research organizations. It encourages proactive identification and resolution of potential issues, leading to more efficient trial conduct and increased confidence in the reliability of clinical data.
3 Questions with: Prof. Piotr Słomka Large language models are entering nuclear cardiology at a pace that makes the usual…
How Axcellant helped a diagnostic study overcome isotope supply, manufacturing, and logistics constraints In radiopharmaceutical development, we often say that…
Europe’s clinical trials market is entering a more practical phase in its approach to competitiveness. With the Clinical Trials Regulation…
Copyright @ 2026 Axcellant